Kirkland and Wachtell lead for $74 billion pharma deal

Bristol-Myers Squibb has tapped Kirkland & Ellis to handle antitrust issues stemming from the pharmaceutical company’s $74 billion purchase of Celgene, which has retained Wachtell Lipton Rosen & Katz.

Get unlimited access to all Global Competition Review content